CNTB vs. SPRO, TPST, CRVS, ALRN, MRNS, BYSI, LFVN, ANEB, VACC, and LPTX
Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Spero Therapeutics (SPRO), Tempest Therapeutics (TPST), Corvus Pharmaceuticals (CRVS), Aileron Therapeutics (ALRN), Marinus Pharmaceuticals (MRNS), BeyondSpring (BYSI), LifeVantage (LFVN), Anebulo Pharmaceuticals (ANEB), Vaccitech (VACC), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
Spero Therapeutics (NASDAQ:SPRO) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Spero Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 314.20%. Connect Biopharma has a consensus price target of $6.50, indicating a potential upside of 354.55%. Given Spero Therapeutics' higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Spero Therapeutics.
25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 4.5% of Spero Therapeutics shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Spero Therapeutics has a net margin of 21.98% compared to Spero Therapeutics' net margin of 0.00%. Connect Biopharma's return on equity of 38.54% beat Spero Therapeutics' return on equity.
In the previous week, Spero Therapeutics had 1 more articles in the media than Connect Biopharma. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 0.00 equaled Spero Therapeutics'average media sentiment score.
Spero Therapeutics received 184 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 69.57% of users gave Connect Biopharma an outperform vote while only 69.20% of users gave Spero Therapeutics an outperform vote.
Spero Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500.
Spero Therapeutics has higher revenue and earnings than Connect Biopharma.
Summary
Spero Therapeutics beats Connect Biopharma on 8 of the 12 factors compared between the two stocks.
Get Connect Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Connect Biopharma Competitors List
Related Companies and Tools
